

ASX Announcement: 21 July 2026 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX: OIL)

Head and Neck Study Progressing Ahead of Schedule

Stage 2 of the first-in-human head and neck cancer imaging study at St John of God Murdoch Hospital utilising Optiscan's InVue™ and InForm™ platforms has commenced ahead of schedule, accelerating clinical validation, FDA regulatory evidence generation and commercial readiness.

HIGHLIGHTS

- Stage 2 of the ground-breaking clinical study for head and neck cancer live imaging currently being undertaken at Perth's St John of God Murdoch Hospital and utilising Optiscan's InVue™ and InForm™ platforms has commenced.
- Advancement of the study from Stage 1 ex vivo imaging was approved by the St John of God Murdoch Hospital's Human Research Ethics Committee, a decision based on the rate, quality and variety of tissues imaged to date.
- Stage 2 of the study will focus on obtaining in vivo images during surgery using Optiscan InVue™ supplemented by ex vivo imaging using the Optiscan InForm™ device.
- The quicker-than-expected progression to Stage 2 of the study will result in both time and cost efficiency benefits.
- Imaging and pathology data generated from the study will support US FDA regulatory submissions and advance Optiscan's oral cancer AI imaging algorithm.



Figure 1: Optiscan InVue™ and Optiscan InForm™ devices with members of the Company's R&D and clinical teams

Optiscan Imaging Limited (ASX:OIL) ('Optiscan' or the 'Company') is pleased to announce Stage 2 of its ground-breaking clinical study for head and neck cancer imaging at St John of God Murdoch Hospital ('**SJG Murdoch**') in Perth has commenced ahead of schedule. This achievement reflects the strong progress made to date in the study and the accelerated accumulation of usable data that comes with it, supported by approval from the SJG Human Research Ethics Committee to advance to the next phase.

The study, which is the first human clinical study to image head and neck cancer tissues in vivo during surgery, is being conducted at SJG Murdoch, in collaboration with Australian Clinical Labs, utilising Optiscan InVue™ precision surgery and Optiscan InForm™ digital pathology platforms.

The study is evaluating Optiscan InVue™ for real-time intraoperative imaging at SJG Murdoch, and Optiscan InForm™ for digital pathology analysis at Australian Clinical Labs.

ACCELERATING CLINICAL PROGRESS

The research is designed to assess the performance of Optiscan's imaging technology in surgical settings through real-time microscopic visualisation during procedures, while also contributing data to the ongoing development of the Company's oral cancer AI imaging algorithms.

This accelerated progression of the study enables Optiscan to expand the types of tissues that can be imaged in the head and neck region and simultaneously result in significant time and cost savings. Imaging and pathology data generated from the study will also support Optiscan's upcoming US FDA regulatory submissions, which will collate imaging data from multiple studies to demonstrate the wide applicability of the Company's platform technology.

The study which was initiated late last year (see ASX Announcement dated 3 December 2025) is being led by Perth-based head and neck cancer surgeon Dr Chady Sader, who has assisted the Company in recruiting its first 10 cases in Stage 1. Imaging from this initial set of cases were used to support the accelerated transition to Stage 2. Australian Clinical Labs continues to support the study through provision of pathology specimen analysis using the Optiscan InForm™ platform across both fresh and fixed tissue samples.

Leveraging the previously announced collaboration agreements with Australian Clinical Labs (see ASX Announcement dated 10 November 2025) and Long Grove Pharmaceuticals (see ASX Announcement dated 23 June 2025), the study will be utilising sodium fluorescein as the contrast agent in combination with the Optiscan InVue™ device.

The program is an important step in validating how real-time microscopic imaging could potentially assist surgeons in assessing tissue structures and surgical margins during complex head and neck cancer procedures.




Figure 2: Current standard surgical workflow compared to real-time imaging with Optiscan InVue™

CLINICAL, REGULATORY AND COMMERCIAL SIGNIFICANCE

Clinical significance: Stage 2 enables live intraoperative imaging during head and neck cancer surgery, supporting assessment of tissue architecture and surgical margins in procedures where real-time decision-making is clinically important.

Regulatory significance: The study will generate paired imaging and pathology evidence across fresh, fixed and in vivo tissue settings, strengthening the dataset intended to support Optiscan's US FDA submissions and future US clinical study design.

Commercial significance: Demonstrating workflow integration in a complex surgical oncology setting supports future adoption of Optiscan InVue™ and Optiscan InForm™ across precision surgery, digital pathology and broader cancer imaging applications.



Figure 3: FDA milestone progress for Optiscan's InVue™ and InForm™ devices

CEO COMMENT

Optiscan CEO and Managing Director, Dr Camile Farah, said:

“We are thrilled to see Stage 2 of the SJOG study utilising our InVue™ and InForm™ platforms commence ahead of initial expectations. This achievement is a testament to the ease of integration of both these innovative platforms into surgical and pathology workflows, as well as the strength of the collaboration between Optiscan, SJOG, and Australian Clinical Labs.”

“This study is proving to be the perfect vehicle to evaluate our imaging technologies in head and neck cancer surgery within a real-world clinical environment. Its Stage 1 deliverables have Optiscan well on the way to demonstrating how real-time microscopic imaging can potentially support surgeons with tissue assessment and surgical decision-making during complex oncological procedures.”

“Importantly, the study looks to be delivering Optiscan more than just clinical development-related benefits. It is also helping advance our broader intent to validate the Optiscan platform across multiple tissue types, procedures, and healthcare settings, with the data generated via the study expected to contribute to multiple strategic priorities across the business. The latter priorities are wide-ranging, and include AI development, future US clinical activities, and regulatory pathways.”

PRINCIPAL INVESTIGATOR COMMENT

Lead Investigator on the SJG Study, Dr Chady Sader, said:

“I am encouraged by the rate of recruitment, the quality of images produced to date and their concordance with standard histopathology. Progression to live imaging is an important next step in evaluating how this technology may assist surgeons during head and neck cancer procedures.”

“The imaging collected so far supports continued investigation of Optiscan InVue™ in this setting, particularly its potential role in supporting tissue assessment and surgical margin evaluation.”

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
T: +61 3 9538 3333
E: ceo@optiscan.com

Media & Investor Enquiries
The Capital Network
Julia Maguire
T: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

About St John of God Murdoch Hospital

St John of God Murdoch Hospital, located in Perth, is one of Western Australia's leading private health campuses. The Hospital was established in 1994, and provides a wide range of medical and surgical services. There has additionally been significant growth in research at the Hospital, in the areas of clinical oncology trials, orthopaedics, emergency medicine, intensive care, cardiology and nursing-led research. Many of its research studies are delivering impressive results, with the focus on patient-centred management and innovative approaches to evaluating patient outcomes.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.